COVID-19疫情期间乳腺活检建议与乳腺癌诊断变化
基于乳腺癌症监测联盟66家机构2019年1月至2020年9月的前瞻性数据二次分析,比较疫情期间(2020年3-9月)与2019年同期乳腺活检建议及癌症诊断数。结果显示疫情期间活检建议及癌症诊断显著减少(24% fewer,P<.001),主要因筛查检出癌症减少38%(P<.001),有症状癌症仅减少7%(P=.27)。亚裔和西班牙裔女性下降幅度最大。
要点
- 疫情期间乳腺活检建议及癌症诊断较2019年同期减少24%,主要因筛查检出癌症减少38%。
- 有症状癌症诊断减少幅度较小(7%),提示有症状患者仍应积极活检。
- 亚裔和西班牙裔女性癌症诊断下降幅度最大(分别53%和43%),需关注种族差异。
诊断标准与关键数值
- 疫情期间(2020年3-9月)活检建议及癌症诊断1650例,较2019年同期2171例减少24%(P<.001)。
- 筛查检出癌症2020年722例,较2019年1169例减少38%(P<.001);有症状癌症2020年895例,较2019年965例减少7%(P=.27)。
- 亚裔女性癌症诊断减少53%(67 vs 142,P=.06),西班牙裔减少43%(82 vs 145,P=.13),黑人女性减少27%(210 vs 287,P=.21),非西班牙裔白人减少17%(1128 vs 1357,P=.09)。
临床应用与阅片要点
- 疫情期间筛查中断导致筛查检出癌症减少,阅片时需注意可能漏诊的筛查病例。
- 有症状患者癌症诊断减少幅度较小,提示有症状者仍应积极活检,不应因疫情延误。
- 亚裔和西班牙裔女性癌症诊断下降更明显,报告时需关注种族差异对诊断延迟的影响。
局限性
- 本研究为二次分析,可能存在未测量的混杂因素。
- 部分亚组(如亚裔、西班牙裔)样本量较小,统计效能有限。
- 研究仅纳入乳腺癌症监测联盟机构,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The COVID-19 pandemic reduced mammography use, potentially delaying breast cancer diagnoses. Purpose To examine breast biopsy recommendations and breast cancers diagnosed before and during the COVID-19 pandemic by mode of detection (screen detected vs symptomatic) and women's characteristics. Materials and Methods In this secondary analysis of prospectively collected data, monthly breast biopsy recommendations after mammography, US, or both with subsequent biopsy performed were examined from 66 facilities of the Breast Cancer Surveillance Consortium between January 2019 and September 2020. The number of monthly and cumulative biopsies recommended and performed and the number of subsequent cancers diagnosed during the pandemic period (March 2020 to September 2020) were compared with data from the prepandemic period using Wald χ2 tests. Analyses were stratified by mode of detection and race or ethnicity. Results From January 2019 to September 2020, 17 728 biopsies were recommended and performed, with 6009 cancers diagnosed. From March to September 2020, there were substantially fewer breast biopsy recommendations with cancer diagnoses when compared with the same period in 2019 (1650 recommendations in 2020 vs 2171 recommendations in 2019 [24% fewer], P < .001), predominantly due to fewer screen-detected cancers (722 cancers in 2020 vs 1169 cancers in 2019 [38% fewer], P < .001) versus symptomatic cancers (895 cancers in 2020 vs 965 cancers in 2019 [7% fewer], P = .27). The decrease in cancer diagnoses was largest in Asian (67 diagnoses in 2020 vs 142 diagnoses in 2019 [53% fewer], P = .06) and Hispanic (82 diagnoses in 2020 vs 145 diagnoses in 2019 [43% fewer], P = .13) women, followed by Black women (210 diagnoses in 2020 vs 287 diagnoses in 2019 [27% fewer], P = .21). The decrease was smallest in non-Hispanic White women (1128 diagnoses in 2020 vs 1357 diagnoses in 2019 [17% fewer], P = .09). Conclusion There were substantially fewer breast biopsies with cancer diagnoses during the COVID-19 pandemic from March to September 2020 compared with the same period in 2019, with Asian and Hispanic women experiencing the largest declines, followed by Black women. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Heller in this issue.
引用
- Lowry KP, Bissell MCS, Miglioretti DL, et al. Breast Biopsy Recommendations and Breast Cancers Diagnosed during the COVID-19 Pandemic. Radiology. 2021. PMID: 34665032. doi:10.1148/radiol.2021211808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。